billHR6396Event Wednesday, December 3, 2025Analyzed

Kid PROOF Act of 2025

Neutral

Summary

HR6396 (Kid PROOF Act) expands eligible uses of existing SUPPORT Act grants for pediatric suicide and overdose prevention but authorizes no new funding and remains in early committee stage. No measurable revenue impact on any publicly traded company.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR6396 is a scope-expansion bill with zero new funding — no revenue impact on any publicly traded company.
  • 2.The bill has been stalled in committee since December 2025 with no markup activity; low probability of near-term passage.
  • 3.Even if enacted, the grant reallocation is too small to move financial results for any for-profit healthcare company.

Market Implications

No actionable market implications. HR6396 is legislative noise for investors — a procedural authorization amendment with no dollar figure attached. Retail investors should not adjust positions based on this bill. If the bill progresses to a vote with a new appropriation attached, that would be a different analysis; currently, there is no market signal.

Full Analysis

1) What happened and its current status: On December 3, 2025, Representative John James (R-MI) introduced HR6396, the Kid PROOF Act, which amends Section 7102(c) of the SUPPORT for Patients and Communities Act (42 U.S.C. 290bb-7a(c)). The bill was referred to both the House Committee on Energy and Commerce and the House Committee on Education and Workforce. As of April 30, 2026, no further actions have been taken — the bill has not been marked up, reported out, or scheduled for a vote in either committee. It is an early-stage, bipartisan bill (4 cosponsors: Dingell, Salazar, Craig) with low legislative velocity. 2) The money trail: The bill authorizes zero new funding. It only expands the scope of allowable activities under existing SUPPORT Act grants — specifically allowing grantees to use funds for pediatric suicide prevention interventions and to provide certain counseling and supplies to parents. The SUPPORT Act (passed in 2018) already had an authorized but largely unfunded grant program. No appropriation is provided in this bill. The Congressional Budget Office would likely score this as having no significant cost, as it merely re-permits existing grant funds to be spent on additional categories of activities. 3) Structural winners and losers: Because this bill does not appropriate new money, there are no direct revenue increases for any healthcare company. Providers that already receive SUPPORT Act grants — community health centers, tribal health programs, children’s hospitals — may allocate existing grant dollars differently, but this is a reallocation within existing budgets, not new money. For-profits like hospitals (HCA, THC, UHS) or managed care organizations (UNH, CI, CNC) see zero revenue impact. The bill does not affect reimbursement rates, coverage mandates, or patient volumes. Behavioral health pure-play companies like Acadia Healthcare (ACHC) or multi-state outpatient providers are not meaningfully affected because the grant expansion is small, discretionary, and not tied to any volume-based funding formula. 4) Competitive landscape: The pediatric behavioral health market is dominated by nonprofit and academic medical centers for inpatient care, and a fragmented mix of for-profit and nonprofit outpatient providers. No single publicly traded company holds a dominant share of the specific grant-funded activities expanded by this bill (parental counseling on lethal means safety, supply distribution). Even if the grant reallocation modestly increased demand for these services, the total addressable market shift is negligible relative to the revenues of any publicly traded company. 5) Timeline: The bill must be marked up and voted out of both the Energy and Commerce Committee and the Education and Workforce Committee, then pass the full House, then clear the Senate Finance Committee and full Senate, then be signed into law. Given the bill’s introduction over 150 days ago with zero committee action, passage is uncertain and likely months away — if it advances at all. The 119th Congress runs through January 2027, so there is time, but no momentum.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.